The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Effect Of Fluconazole, A Moderate CYP3A4 Inhibitor, On The Single-Dose Pharmacokinetics Of Fesoterodine In Healthy Subjects.

This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.

Inclusion Criteria:

• Healthy subjects between the ages of 18 and 55 years

Exclusion Criteria:

• Not healthy subjects. subjects with acute or chronic medical or psychiatric condition or laboratory abnormality